Hormone Therapy and Cardiovascular Risk in Premenopausal Breast Cancer Patients

Posted: 01/03/2025 | By: Melissa E. Fryman, MS

The cardiovascular impact of hormone therapies and ovarian suppression in premenopausal patients with breast cancer is unknown. A recent study published in JACC: CardioOncology aimed to test the hypothesis that use of aromatase inhibitors plus ovarian suppression would be associated with greater risk of cardiovascular disease than tamoxifen in these patients.

Question 1 of 5

Over a median follow-up time of 1.55 years, the incidence rate of cardiovascular disease (CVD) was among users of aromatase inhibitors plus ovarian suppression vs _ for tamoxifen users.

Hormone Therapy and Cardiovascular Risk in Premenopausal Breast Cancer Patients

Posted: 01/03/2025 | By: Melissa E. Fryman, MS

Question 1 of 5

Over a median follow-up time of 1.55 years, the incidence rate of cardiovascular disease (CVD) was among users of aromatase inhibitors plus ovarian suppression vs _ for tamoxifen users.

Choose 1

CategoriesView All Quizzes

Tumor Type

Additional Topics

Conference Coverage

Posted: 01/03/2025 | By: Melissa E. Fryman, MS

list Quiz Information

Question 1 of 5

Over a median follow-up time of 1.55 years, the incidence rate of cardiovascular disease (CVD) was ____ among users of aromatase inhibitors plus ovarian suppression vs _____ for tamoxifen users.

Choose 1

Trending

CategoriesView All Quizzes

Tumor Type

Additional Topics

Conference Coverage

Over a median follow-up time of 1.55 years, the incidence rate of cardiovascular disease (CVD) was among users of aromatase inhibitors plus ovarian suppression vs _ for tamoxifen users.